Can we improve patient selection for phase I clinical trials (phI1) based on immuno-oncology score prognostic index (VIO)?
I. Matos Garcia
◽
C. Hierro
◽
J. Martin-Liberal
◽
C. VIAPLANA
◽
A. Azaro
◽
...
2021 ◽
Vol 155
◽
pp. 168-178
Ignacio Matos
◽
Guillermo Villacampa
◽
Cinta Hierro
◽
Juan Martin-Liberal
◽
Roger Berché
◽
...
Laura Callan
◽
Jason Vickress
◽
Eugene Wong
2010 ◽
Vol 8
(7)
◽
pp. 189-190
S. Sandhu
◽
C. Massard
◽
D. Papadatospastos
◽
T. Yap
◽
D. Olmos
◽
...
2019 ◽
Vol 105
(1)
◽
pp. S151
L. Callan
◽
J. Vickress
◽
E. Wong
◽
M.I. Lock
2019 ◽
Vol 105
(1)
◽
pp. E581-E582
L. Callan
◽
J. Vickress
◽
E. Wong
◽
M.I. Lock
2019 ◽
Vol 139
◽
pp. S57-S58
Laura Callan
◽
Jason Vickress
◽
Eugene Wong
◽
Michael Lock
2008 ◽
Vol 26
(15_suppl)
◽
pp. 2508-2508
◽
H. Arkenau
◽
J. Barriuso
◽
D. Olmos
◽
C. Barlow
◽
J. S. De Bono
◽
...
2005 ◽
Vol 1
(3)
◽
pp. 242
Scott A. Shikora
◽
Roand Maude-Griffin
2019 ◽
Vol 69
(5)
◽
pp. 1645-1646
S. Keyhani
◽
E. Madden
◽
E.M. Cheng
◽
D.M. Bravata
◽
E. Halm
◽
...
Ziad Farah
◽
Oseme Etomi
◽
Nikita Arumalla
◽
Stephen Kelly